Determination of decapeptide LXT-101 in plasma by HPLC-MS/MS and its pharmacokinetics in Beagle dogs.
- Author:
Ai-ying KONG
1
;
Zhen-qing ZHANG
;
Jian-zhong QIAO
;
Fan ZHANG
;
Wen-xia ZHOU
;
Ke-liang LIU
;
Jin-xiu RUAN
Author Information
1. Key Lab of Drug Metabolism and Pharmacokinetics, Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, Beijing 100850, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Antineoplastic Agents;
administration & dosage;
blood;
pharmacokinetics;
Area Under Curve;
Chromatography, High Pressure Liquid;
Dogs;
Gonadotropin-Releasing Hormone;
antagonists & inhibitors;
Injections, Intramuscular;
Male;
Oligopeptides;
administration & dosage;
blood;
pharmacokinetics;
Spectrometry, Mass, Electrospray Ionization
- From:
Acta Pharmaceutica Sinica
2008;43(9):946-950
- CountryChina
- Language:Chinese
-
Abstract:
This paper developed a sensitive and specific liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/MS) method for the determination of decapeptide LXT-101 in Beagle dog plasma. Plasma samples spiked with internal standard (IS) were treated with acetonitrile to precipitate the protein. Selected reaction monitoring (SRM) using the precursor --> product ion combinations of m/z 472.1-->587.9 and m/z 502.8-->633.8 were used to quantify LXT-101 and IS, respectively. The linear calibration curves were obtained in the concentration range of 0.5 - 500.0 ng x mL(-1). The limit of quantification (LOQ) was 0.5 ng x mL(-1). The inter-day and intra-day precision (RSD) across three validation run over the entire concentration range was below 10.9%, and the accuracy (RE) was within +/- 1.8%. The main pharmacokinetic parameters of LXT-101 after muscle injection of 20 microg x kg(-1) were as follows, AUC(0-t): (176.8 +/- 116.7) microg x h x L(-1), MRT(0-t): (2.52 +/- 0.53) h, T(1/2): (1.4 +/- 0.3) h; CL: (0.16 +/- 0.09) L x h(-1) x kg(-1), and Vd: (0.30 +/- 0.16) L x kg(-1), respectively. The method is proved to be specific, sensitive and suitable for the investigation of LXT-101 pharmacokinetics in Beagle dog.
